PAVM

Pavmed

• Dow Jones·1d ago

  PAVmed Is Maintained at Buy by Ascendiant Capital

• Dow Jones·1d ago

  PAVmed Price Target Cut to $65.00/Share From $510.00 by Ascendiant Capital

• Reuters·1d ago

  PAVmed unit Lucid Diagnostics to join Needham Virtual Healthcare Conference fireside chat

• Reuters·1d ago

  Lucid Diagnostics CEO to join Needham Virtual Healthcare Conference fireside chat

• Reuters·4d ago

  PAVmed files Form 3 initial beneficial ownership statement for Tasso Partners LLC

• Dow Jones·04/02 12:08

  *PAVmed: Virgilio to Serve as CEO of Subsidiaries PortIO Inc, Octeris Inc >PAVM

• Reuters·04/02 12:07

  PAVmed names Joseph Virgilio SVP, chief business officer for medical devices

• Dow Jones·04/02 12:07

  *PAVmed: Octeris, Inc. Subsidiary Formed to Advance Endoscopic Esophageal Imaging Tech Recently Licensed From Duke University >PAVM

• TipRanks·03/31 13:28

  PAVmed price target lowered to $16 from $60 at Maxim

• TipRanks·03/30 13:11

  PAVmed Reports 2025 Results, Strengthens Balance Sheet

• Reuters·03/30 12:12

  PAVmed FY25 net loss narrows to $3.8 million; revenue falls to $0.1 million

• Seeking Alpha·03/30 12:11

  PAVmed Non-GAAP EPS of -$1.05

• Reuters·03/30 12:07

  PAVMED INC - Q4 2025 NON-GAAP ADJ LOSS $0.9 MLN, $1.05 PER SHARE

• Benzinga·03/30 11:11

  Earnings Scheduled For March 30, 2026

• Seeking Alpha·03/29 22:00

  Here are the major earnings before the open Monday